Combining CTLA-4 and PD-1 inhibitors could have a synergistic antitumor effect, resulting in enhanced activity and increased infiltration of TILs, as well as a decrease in Tregs in the CCA microenvironment. The gene discussed is CTLA4; the disease is cholangiocarcinoma.